Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 349,005,824
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 76,450 M
  • Annual Income, $ 1,300 M
  • 36-Month Beta 0.74
  • Price/Sales 4.60
  • Price/Cash Flow 15.81
  • Price/Book 4.75

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.15 +7.07%
on 02/05/18
147.44 -11.30%
on 01/23/18
-17.36 (-11.72%)
since 01/22/18
3-Month
122.15 +7.07%
on 02/05/18
148.32 -11.83%
on 01/17/18
-6.51 (-4.74%)
since 11/22/17
52-Week
119.48 +9.46%
on 02/23/17
148.32 -11.83%
on 01/17/18
+11.26 (+9.42%)
since 02/22/17

Most Recent Stories

More News
Why Is Johnson & Johnson (JNJ) Down 8.5% Since its Last Earnings Report?

ohnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JNJ : 130.43 (+0.40%)
Global Hospital Supplies Market Briefing 2018 Featuring Johnson & Johnson, GE Healthcare, Cardinal Health, Medline Industries & B. Braun Melsungen - ResearchAndMarkets.com

The "Hospital Supplies Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.

JNJ : 130.43 (+0.40%)
ERLEADA (Apalutamide), the First FDA-Approved Treatment for Non-Metastatic, Castration-Resistant Prostate Cancer, Available for Order at Biologics, Inc.

Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected by the Janssen Pharmaceutical Companies of Johnson & Johnson(1)...

JNJ : 130.43 (+0.40%)
J&J Does Best in Attracting Young, High-Achieving Immuno-Oncology Researchers, According to Data Analytics Firm hiQ Labs

Johnson & Johnson is the premier destination for elite, high-achieving young Immuno-Oncology (I-O) professionals, according to a new study issued by hiQ Labs, a research firm that analyzes publicly available...

JNJ : 130.43 (+0.40%)
Global Contact Lenses and Solutions Strategic Business Report 2018 Featuring Alcon, Bausch & Lomb, CooperVision, Ginko, Johnson & Johnson and St. Shine Optical

The "Contact Lenses and Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

JNJ : 130.43 (+0.40%)
Johnson & Johnson to Participate in Cowen 38th Annual Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13, at The Boston Marriott Copley Place, Boston. Ashley McEvoy, Company Group Chairman, Consumer...

JNJ : 130.43 (+0.40%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Johnson & Johnson of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 - JNJ

The following statement is being issued by Levi & Korsinsky, LLP:

JNJ : 130.43 (+0.40%)
What's in the Cards for Geron (GERN) This Earnings Season?

With no approved product in Geron's (GERN) portfolio, investor focus is likely to remain on its sole pipeline candidate, imetelstat, in the Q4 release.

EXAS : 46.78 (+0.30%)
JNJ : 130.43 (+0.40%)
EXEL : 29.23 (+0.83%)
GERN : 2.28 (+1.33%)
Iron Deficiency Anemia - Pipeline Insight, 2018 Featuring Johnson & Johnson, Novartis, Pieris Pharmaceuticals, Rockwell Medical & Shield Therapeutics - ResearchAndMarkets.com

The "Iron Deficiency Anemia - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

JNJ : 130.43 (+0.40%)
NVS : 85.53 (+0.75%)
PIRS : 8.31 (+2.34%)
Johnson & Johnson Medical Devices Companies Acquire Orthotaxy to Develop Next-Generation Robotic-Assisted Surgery Platform in Orthopaedics

Johnson & Johnson Medical Devices Companies, through French affiliate Apsis S.A.S., announced today the acquisition of Orthotaxy, a privately-held developer of software-enabled surgery technologies, including...

JNJ : 130.43 (+0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 133.30
1st Resistance Point 131.61
Last Price 130.43
1st Support Level 129.04
2nd Support Level 128.16

See More

52-Week High 148.32
Fibonacci 61.8% 137.30
Fibonacci 50% 133.90
Fibonacci 38.2% 130.50
Last Price 130.43
52-Week Low 119.48

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.